Increased out-of-pocket costs for antiepileptic drugs were associated with decreased adherence, higher healthcare utilization, and higher spending among US commercial health plan beneficiaries with epilepsy.
David M. Labiner, MD
Advertisement
Articles by David M. Labiner, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
3
Defunding Co-Payment Assistance Disrupted nAMD Care
4
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
5